Sugi Predict

Sugi Predict / Compounds / SCHEMBL1643386

SCHEMBL1643386

SCHEMBL1643386

CC12CCC(C(O)C1=O)C2(C)C

nearest known ligand 0.42

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
▸ PTPN1 P18031 2/20 0.42
▸ ALDH1A1 P00352 2/20 0.40
▸ SMN1; SMN2 Q16637 1/20 0.40
▸ HSD17B10 Q99714 1/20 0.40
▸ MEN1 O00255 1/20 0.39
▸ LMNA P02545 1/20 0.39
▸ MAPT P10636 1/20 0.39
▸ KMT2A Q03164 1/20 0.39
▸ CNR2 P34972 2/20 0.37
▸ DPP4 P27487 1/20 0.36
▸ CYP19A1 P11511 7/20 0.33
▸ L3MBTL1 Q9Y468 1/20 0.32
▸ G6PD P11413 2/20 0.31
▸ PTPN2 P17706 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11274360 1.00 PTPN1 (0.42) PTPN1ALDH1A1SMN1; SMN2HSD17B10MEN1
SCHEMBL21649182 0.78 ALDH1A1 (0.42) PTPN1ALDH1A1SMN1; SMN2HSD17B10MEN1
SCHEMBL13244721 0.77 ALDH1A1 (0.41) PTPN1ALDH1A1SMN1; SMN2HSD17B10MEN1
SCHEMBL18817582 0.77 ALDH1A1 (0.41) PTPN1ALDH1A1SMN1; SMN2HSD17B10MEN1
SCHEMBL18817586 0.77 ALDH1A1 (0.41) PTPN1ALDH1A1SMN1; SMN2HSD17B10MEN1
SCHEMBL15151590 0.77 ALDH1A1 (0.41) PTPN1ALDH1A1SMN1; SMN2HSD17B10MEN1
SCHEMBL17255910 0.76 PTPN1 (0.40) PTPN1ALDH1A1SMN1; SMN2HSD17B10MEN1
SCHEMBL4565223 0.76 PTPN1 (0.40) PTPN1ALDH1A1SMN1; SMN2HSD17B10MEN1
SCHEMBL503441 0.76 PTPN1 (0.40) PTPN1ALDH1A1SMN1; SMN2HSD17B10MEN1
SCHEMBL4372039 0.76 PTPN1 (0.40) PTPN1ALDH1A1SMN1; SMN2HSD17B10MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 202 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-110538141-A oxycocamphor injection and preparation method thereof JIANGSU CAREPHAR PHARMACEUTICAL CO LTD 2019-12-06 — — CN claimed
CN-110540494-A Oxycocamphor crystal-form compound and preparation method thereof JIANGSU CAREPHAR PHARMACEUTICAL CO LTD 2019-12-06 — — CN claimed
CN-110540495-A synthetic process of camphor oxide JIANGSU CAREPHAR PHARMACEUTICAL CO LTD 2019-12-06 — — CN claimed
CN-106117032-B Oxycamphor isolation and purification method 长春大政药业科技有限公司 2018-10-16 — — CN claimed
CN-105001108-A Optical pure 3,4-dimethyl glutamic acid derivative preparation method UNIV HEBEI SCIENCE & TECH 2015-10-28 — — CN claimed
CN-104974055-A Preparation method of optically pure 3-methyl glutamic acid derivative UNIV HEBEI SCIENCE & TECH 2015-10-14 — — CN claimed
CN-101468945-B Technique for synthesizing vitacampher CHANGCHUN DAZHENG PHARMACEUTICAL TECHNOLOGY CO., LTD. (CN) 2011-12-28 — — CN claimed
CN-101468945-A Technique for synthesizing vitacampher CHANGCHUN DAZHENG PHARMACEUTIC (CN) 2009-07-01 — — CN claimed
US-20040223946-A1 Adhesive treatment for insect and related bites CLOSURE MEDICAL CORPORATION 2004-11-11 — — US claimed
CN-1528754-A Beta-hydroxy-alpha-amino acid and its derivatives and synthesizing method for preparing template 兰州大学 2004-09-15 — — CN claimed
CN-1294519-A Pharmaceutical composition containing a compound having an activity of promoting the absorption of an active ingredient INPHARMA SA (CH) 2001-05-09 — — CN claimed
EP-1073470-A1 PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS INPHARMA S.A. (CH) 2001-02-07 — — EP claimed
WO-2000048636-A1 PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS INPHARMA S.A. (CH) 2000-08-24 — — WO claimed
US-4318784-A ELECTROCHEMICAL REDOX SYSTEM NATIONAL RESEARCH DEVELOPMENT CORPORATION (GB) 1982-03-09 — — US claimed
EP-0020355-A1 ENZYMATIC PROCESSES. NAT RES DEV (GB) 1981-01-07 — — EP claimed
WO-1980000453-A1 ENZYMATIC PROCESSES NAT RES DEV (GB) 1980-03-20 — — WO claimed
US-20240074995-A1 METHODS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH AN ABNORMAL INFLAMMATORY RESPONSES FIRST WAVE BIO, INC. 2024-03-07 — — US disclosed
CN-117597327-A Pharmaceutical preparation 第一波动生物制药股份有限公司 2024-02-23 — — CN disclosed
EP-0020355-A1 ENZYMATIC PROCESSES. NAT RES DEV (GB) 1981-01-07 — — EP disclosed
WO-1980000453-A1 ENZYMATIC PROCESSES NAT RES DEV (GB) 1980-03-20 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040223946-A1 Adhesive treatment for insect and related bites CUTA, FGB, ICAM1 PTPN1 4094/4885ALDH1A1 3581/4885SMN1; SMN2 2100/4885
US-20240074995-A1 METHODS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH AN ABNORMAL INFLAMMATORY RESPONSES FH, CS, ECHS1 PTPN1 2463/4885ALDH1A1 2174/4885SMN1; SMN2 1037/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.